Organovo Announces Close of the Sale of FXR Program to Eli Lilly and Company

Core Insights - Organovo Holdings, Inc. has successfully closed the sale of its FXR program, including the lead asset FXR314, to Eli Lilly and Company on March 25, 2025 [1][2] Group 1: Transaction Details - Organovo will receive an upfront payment and future milestone payments as FXR314 achieves key regulatory and commercial milestones [2] - Eli Lilly is acquiring all commercial and intellectual property rights to Organovo's FXR program for worldwide development and will handle all future clinical development [2] Group 2: Company Overview - Organovo is a clinical stage biotechnology company focused on developing drugs that are effective in three-dimensional (3D) human tissues [3] - The company utilizes proprietary technology to create 3D human tissues that replicate essential aspects of native human tissue composition, architecture, function, and disease [3]